Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.33 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8278256 | 1.00 | REN (0.33) | RENADRB3ADRA2BADRA2CRAMP1 | |
| SCHEMBL8294160 | 0.95 | DRD2 (0.35) | RENADRB3ADRA2BADRA2CRAMP1 | |
| SCHEMBL8165110 | 0.93 | DDB1 (0.34) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12770115 | 0.93 | DDB1 (0.34) | ADRB3ADRA2BADRA2C | |
| SCHEMBL5611990 | 0.89 | RAMP1 (0.34) | RENADRB3ADRA2BADRA2CRAMP1 | |
| SCHEMBL8294626 | 0.87 | MEN1 (0.37) | ADRB3ADRA2BADRA2CPDE4B | |
| SCHEMBL13896342 | 0.87 | SCN9A (0.32) | ADRB3ADRA2BADRA2CDRD2 | |
| SCHEMBL1655060 | 0.85 | ADRB3 (0.46) | RENADRB3ADRA2BADRA2CRAMP1 | |
| SCHEMBL3799240 | 0.85 | ADRB3 (0.46) | RENADRB3ADRA2BADRA2CRAMP1 | |
| SCHEMBL13818335 | 0.85 | ADRB3 (0.46) | RENADRB3ADRA2BADRA2CRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | REN 138/4885ADRB3 4337/4885ADRA2B 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.